表紙
市場調査レポート

バンコマイシン耐性腸球菌感染症:パイプライン製品の分析

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264091
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
バンコマイシン耐性腸球菌感染症:パイプライン製品の分析 Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 112 Pages
概要

バンコマイシン耐性腸球菌の病原性株は、VREと呼ばれ、院内感染の原因となっています。症状は、感染部位によって異なります。細菌は通常、腸・創傷・尿路で感染します。創傷感染の場合は、感染部位は赤く、圧痛があり、腫れます。尿路感染の場合は、背中の痛み、排尿時の灼熱感が生じます。他には、悪心、発熱、悪寒、激しい頭痛、下痢などの症状が見られます。予防には、効果的な衛生の実行が不可欠です。

当レポートでは、バンコマイシン耐性腸球菌感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

バンコマイシン耐性腸球菌感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

バンコマイシン耐性腸球菌感染症:企業で開発中の治療薬

バンコマイシン耐性腸球菌感染症:大学/機関で研究中の治療薬

バンコマイシン耐性腸球菌感染症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

バンコマイシン耐性腸球菌感染症:企業で開発中の製品

バンコマイシン耐性腸球菌感染症:大学/機関で研究中の製品

バンコマイシン耐性腸球菌感染症の治療薬開発に従事している企業

  • Alchemia Limited
  • Alvogen Korea Co., Ltd.
  • Aphios Corporation
  • Cellceutix Corporation
  • Helix BioMedix, Inc.
  • Hsiri Therapeutics, LLC
  • LegoChem Biosciences, Inc
  • Lytix Biopharma AS
  • MGB Biopharma Limited
  • MicuRx Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • Sealife PHARMA GMBH
  • Sentinella Pharmaceuticals, Inc.
  • TAXIS Pharmaceuticals, Inc.
  • Wockhardt Limited

バンコマイシン耐性腸球菌感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

バンコマイシン耐性腸球菌感染症:最近のパイプライン動向

バンコマイシン耐性腸球菌感染症:休止中のプロジェクト

バンコマイシン耐性腸球菌感染症:開発が中止された製品

バンコマイシン耐性腸球菌感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8032IDB

Summary

Global Markets Direct's, 'Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2016', provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections
  • The report reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vancomycin-Resistant Enterococcus faecium Infections therapeutics and enlists all their major and minor projects
  • The report assesses Vancomycin-Resistant Enterococcus faecium Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vancomycin-Resistant Enterococcus faecium Infections Overview
    • Therapeutics Development
  • Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview
  • Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies
  • Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
    • Alchemia Limited
    • Alvogen Korea Co., Ltd.
    • Aphios Corporation
    • Cellceutix Corporation
    • Helix BioMedix, Inc.
    • Hsiri Therapeutics, LLC
    • LegoChem Biosciences, Inc
    • Lytix Biopharma AS
    • MGB Biopharma Limited
    • MicuRx Pharmaceuticals, Inc.
    • Nanotherapeutics, Inc.
    • NovaBay Pharmaceuticals, Inc.
    • NovoBiotic Pharmaceuticals, LLC
    • Oragenics, Inc.
    • Sealife PHARMA GMBH
    • Sentinella Pharmaceuticals, Inc.
    • TAXIS Pharmaceuticals, Inc.
    • Wockhardt Limited
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AM-218 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • auriclosene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chrysophaentin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • closthioamide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Epimerox - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCB-010371 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCB-010699 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Marinus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-IV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAI-107 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAI-603 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OG-253 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ramoplanin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-2078 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Teixobactin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WCK-4086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
      • Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
      • Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
      • Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins
      • May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
      • Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alchemia Limited, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Alvogen Korea Co., Ltd., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corporation, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Cellceutix Corporation, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics, LLC, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Lytix Biopharma AS, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Limited, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Nanotherapeutics, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2016
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2016
  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top